Basal Ganglia HemorrhageRAINBOW-ICHNCT07205263
RAINBOW-ICH Trial of AI Guided Minimally Invasive Neurosurgery for ICH
A study testing AI-assisted robotic-guided endoscopic hematoma evacuation, Conventional craniotomy and AI-assisted robotic-guided puncture and hematoma evacuation in people with Basal Ganglia Hemorrhage and Intraventricular Hemorrhage, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 1 site in China.
Trial summary
Intracerebral hemorrhage (ICH) is one of the most devastating forms of stroke, with high rates of death and disability worldwide. Despite advances in medical and surgical care, effective therapeutic options remain limited. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Basal Ganglia Hemorrhage, Intraventricular Hemorrhage, Brainstem Stroke
- What is being tested?
- AI-assisted robotic-guided endoscopic hematoma evacuation, Conventional craniotomy and AI-assisted robotic-guided puncture and hematoma evacuation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,000 participants
- Where
- 1 siteChina
- Study dates
- 30 Sep 2025to Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Umbrella Trial Inclusion Criteria:
- Age ≥18 years；
- Clinical diagnosis of spontaneous hemorrhagic stroke；
Umbrella Trial Exclusion Criteria:
- Radiologically diagnosed cerebrovascular abnormalities, as well as ischemic infarction converting to intracerebral hemorrhage, or recent (within 1 year) recurrence of intracerebral hemorrhage；
Each substudy will specify additional inclusion and exclusion criteria in the respective Substudy-specific Registration. Patients who fulfill the overall umbrella trial criteria will be assessed for enrollment into each substudy.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000
About this study
Official title: A Multicenter, Randomized, Controlled, Umbrella Trial for Minimally Invasive Neurosurgery With Al-assisted Robotic Guidance for Hemorrhagic Stroke (RAINBOW-ICH)
Intracerebral hemorrhage (ICH) is one of the most devastating forms of stroke, with high rates of death and disability worldwide. Despite advances in medical and surgical care, effective therapeutic options remain limited. To address this gap, the RAINBOW-ICH trial has been designed as a nationwide, multicenter, randomized umbrella trial evaluating the efficacy and safety of AI-assisted, robotic-guided minimally invasive neurosurgery compared with conventional strategies across major ICH subtypes.
Under a single master protocol, RAINBOW-ICH incorporates multiple parallel randomized controlled substudies, each targeting a distinct ICH population-large basal ganglia hemorrhage, moderate basal ganglia hemorrhage, intraventricular hemorrhage, and brainstem hemorrhage. This umbrella design allows efficient use of resources while generating high-quality evidence tailored to the specific needs of different ICH subgroups, thereby supporting a more patient-centered approach to care.
Read the detailed description
Intracerebral hemorrhage (ICH) is a leading cause of stroke-related mortality and long-term disability worldwide. Conventional surgical techniques, including craniotomy and catheter-based drainage, are often associated with significant procedural risks and variable outcomes across clinical settings. Minimally invasive approaches have been proposed to reduce surgical trauma, improve precision, and enhance recovery. Recent studies, such as the ENRICH trial, have provided encouraging evidence that selected patients may benefit from early minimally invasive hematoma evacuation, though results remain heterogeneous and further validation is needed across different ICH subtypes and populations.
The RAINBOW-ICH trial has been established to address this critical gap by systematically evaluating the role of AI-assisted, robotic-guided minimally invasive neurosurgery. Advances in robotics and artificial intelligence have enabled neurosurgeons to achieve greater precision in hematoma evacuation, minimize surgical injury, and improve reproducibility of complex procedures. RAINBOW-ICH is designed as a nationwide, multicenter umbrella trial, conducted under a single master protocol, with multiple parallel randomized controlled substudies. Each substudy focuses on a distinct ICH population and directly compares AI-assisted robotic-guided hematoma evacuation with the conventional standard of care relevant to that subgroup. Specifically, RAINBOW-LBH (NCT06484374) evaluates patients with large basal ganglia hemorrhage, RAINBOW-MBH (NCT06465719) addresses moderate basal ganglia hemorrhage, RAINBOW-IVH (NCT06486480) investigates intraventricular hemorrhage, and RAINBOW-BSH (NCT06459427) targets brainstem hemorrhage.
Within each substudy, participants are randomized to receive either AI-assisted robotic-guided minimally invasive neurosurgery or the control intervention, such as conventional craniotomy, external ventricular drainage, or optimized medical management. All substudies are conducted as multicenter RCTs across China, ensuring adequate and rapid recruitment, generalizability, and rigorous evaluation of interventions in diverse clinical environments.
By integrating minimally invasive neurosurgical technologies with a unified multicenter umbrella trial design, RAINBOW-ICH represents the first large-scale effort in China to rigorously test and compare surgical strategies for ICH. The findings are expected to generate high-quality evidence, refine clinical practice, and ultimately improve neurological outcomes for patients with this devastating disease.
- Conditions
- Basal Ganglia Hemorrhage, Intraventricular Hemorrhage, Brainstem Stroke, Intracranial Hemorrhage, Spontaneous
- Being tested
- AI-assisted robotic-guided endoscopic hematoma evacuation, Conventional craniotomy, AI-assisted robotic-guided puncture and hematoma evacuation, Standard medical management, AI-assisted robotic-guided endoscopic ventricular hematoma evacuation plus external ventricular drainage
- Keywords
- Umbrella Trial, Intraventricular hemorrhage, Brainstem Stroke, Robotic-guided, Basal Ganglia Hemorrhage, Minimally invasive surgery
- Medical subject headings
- Basal Ganglia Hemorrhage, Brain Stem Infarctions, Intracranial Hemorrhages
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AI-assisted robotic-guided endoscopic hematoma evacuationProcedure or surgery
Surgical removal of hematoma using AI-assisted robotic-guided stereotactic navigation and endoscopic aspiration techniques.
Conventional craniotomyProcedure or surgery
Standard open surgical evacuation of hematoma through craniotomy.
AI-assisted robotic-guided puncture and hematoma evacuationProcedure or surgery
AI-assisted robotic-guided stereotactic puncture and aspiration of hematoma.
Standard medical managementOther
Guideline-based conservative therapy without surgical hematoma evacuation.
AI-assisted robotic-guided endoscopic ventricular hematoma evacuation plus external ventricular drainageProcedure or surgery
AI-assisted robotic-guided endoscopic evacuation of ventricular hematoma combined with external ventricular drainage.
External ventricular drainage (EVD)Procedure or surgery
Conventional ventricular catheter placement for hematoma drainage.
| Study group | Role | What they receive |
|---|---|---|
| RAINBOW-LBH substudy | Experimental | This substudy is a prospective, multicenter, randomized, controlled, parallel-group trial with blinded endpoint assessment to evaluate the efficacy and safety of AI-assisted robotic-guided endoscopic hematoma evacuation for patients with large basal ganglia hemorrhage (LBH). Receives: Procedure: AI-assisted robotic-guided endoscopic hematoma evacuation; Procedure: Conventional craniotomy |
| RAINBOW-MBH substudy | Experimental | This substudy is a prospective, multicenter, randomized, controlled, parallel-group trial with blinded endpoint assessment to evaluate AI-assisted robotic-guided puncture and hematoma evacuation for patients with moderate basal ganglia hemorrhage (MBH). Receives: Procedure: AI-assisted robotic-guided puncture and hematoma evacuation; Other: Standard medical management |
| RAINBOW-IVH substudy | Experimental | This substudy is a prospective, multicenter, randomized, controlled, parallel-group trial with blinded endpoint assessment to evaluate AI-assisted robotic-guided endoscopic ventricular hematoma evacuation with external ventricular drainage for patients with intraventricular hemorrhage (IVH) Receives: Procedure: AI-assisted robotic-guided endoscopic ventricular hematoma evacuation plus external ventricular drainage; Procedure: External ventricular drainage (EVD) |
| RAINBOW-BSH substudy | Experimental | This substudy is a prospective, multicenter, randomized, controlled, parallel-group trial with blinded endpoint assessment to evaluate AI-assisted robotic-guided puncture and hematoma evacuation for patients with brainstem hemorrhage (BSH). Receives: Procedure: AI-assisted robotic-guided puncture and hematoma evacuation; Other: Standard medical management |
What is being measured
The primary outcome is the main question the study is designed to answer.
Utility-weighted modified Rankin Scale (UW-mRS)
The mRS is a 7-level ordinal scale used to evaluate functional outcomes after stroke. The categories are defined as follows:
0 = No symptoms
- = No significant disability. Able to carry out all usual activities, despite some symptoms.
- = Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- = Moderate disability. Requires some help, but able to walk unassisted.
- = Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- = Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- = Dead Utility-weighted modified Rankin Scale (UW-mRS) , which applies utility values to each mRS category as shown below： mRS 0= UW-mRS 1；mRS 1= UW-mRS 0.91; mRS 2= UW-mRS 0.76; mRS 3= UW-mRS 0.65; mRS 4= UW-mRS 0.33; mRS 5= UW-mRS 0; mRS 6= UW-mRS 0.
Measured: Umbrella level time frame: 6 months; Substudy specific time frame may differ (details will be included in substudy-specific registration)
Secondary outcomes (5)
Ordinal shift in modified Rankin Scale
Ordinal shift analysis of the modified Rankin Scale (mRS), which measures the degree of disability or dependence in daily activities after stroke. The scale ranges from 0 (no symptoms) to 6 (death). This outcome assesses whether there is a shift toward better or worse functional status across the full ordinal distribution of mRS scores.
Measured: Umbrella level time frame: 6 months; Substudy specific time frame may differ (details will be included in substudy-specific registration)
Excellent functional neurological outcome
Excellent functional neurological outcome means modified Rankin scale (mRS) scores 0-1. The minimum mRS is 0 (no symptoms) while the maximum mRS is 6 (death). The higher the mRS score is the worse outcome is.
Measured: Umbrella level time frame: 6 months; Substudy specific time frame may differ (details will be included in substudy-specific registration)
Independent functional neurological outcome
Independent functional neurological outcome means modified Rankin scale (mRS) scores 0-2. The minimum mRS is 0 (no symptoms) while the maximum mRS is 6 (death). The higher the mRS score is the worse outcome is.
Measured: Umbrella level time frame: 6 months; Substudy specific time frame may differ (details will be included in substudy-specific registration)
Health Related Quality of Life
Health Related Quality of Life based on EuroQol 5 Dimension 5 Level (EQ-5D-5L).The EQ-5D-5L is a generic instrument for describing and valuing health. It assesses five domains: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has five response categories corresponding to: no problems, slight, moderate, severe and extreme problems.
Measured: Umbrella level time frame: 6 months; Substudy specific time frame may differ (details will be included in substudy-specific registration)
Total length of hospital stay
Total length of hospital stay refers to the number of days from the date of hospital admission to the date of discharge.
Measured: Umbrella level time frame: 6 months; Substudy specific time frame may differ (details will be included in substudy-specific registration)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Oct 2025
- Study start30 Sep 2025
- Primary completionDec 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Basal Ganglia HemorrhageStudies of the same condition, open and under way.
- More trials run by Second Affiliated Hospital, Zhejiang University, School of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Huashan Hospital, China-Japan Friendship Hospital
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07205263
- Sponsor's protocol ID
- 2023ZD0505000
- Acronym
- RAINBOW-ICH
- Status last verified
- Aug 2025
- First submitted
- 25 Sep 2025
- Last updated
- 8 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Randomized, Controlled, Umbrella Trial for Minimally Invasive Neurosurgery With Al-assisted Robotic Guidance for Hemorrhagic Stroke (RAINBOW-ICH)
- ClinicalTrials.gov ID
- NCT07205263
- Acronym / sponsor ID
- RAINBOW-ICH / 2023ZD0505000
- Conditions
- Basal Ganglia Hemorrhage, Intraventricular Hemorrhage, Brainstem Stroke, Intracranial Hemorrhage, Spontaneous
- Keywords
- Umbrella Trial, Intraventricular hemorrhage, Brainstem Stroke, Robotic-guided, Basal Ganglia Hemorrhage, Minimally invasive surgery
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of MedicineUniversity, hospital or other
- Collaborators
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Huashan Hospital, China-Japan Friendship Hospital
- Study start
- 30 Sep 2025 (actual)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 3 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Intracerebral hemorrhage (ICH) is one of the most devastating forms of stroke, with high rates of death and disability worldwide. Despite advances in medical and surgical care, effective therapeutic options remain limited. To address this gap, the RAINBOW-ICH trial has been designed as a nationwide, multicenter, randomized umbrella trial evaluating the efficacy and safety of AI-assisted, robotic-guided minimally invasive neurosurgery compared with conventional strategies across major ICH subtypes.
Under a single master protocol, RAINBOW-ICH incorporates multiple parallel randomized controlled substudies, each targeting a distinct ICH population-large basal ganglia hemorrhage, moderate basal ganglia hemorrhage, intraventricular hemorrhage, and brainstem hemorrhage. This umbrella design allows efficient use of resources while generating high-quality evidence tailored to the specific needs of different ICH subgroups, thereby supporting a more patient-centered approach to care.
Detailed description
Intracerebral hemorrhage (ICH) is a leading cause of stroke-related mortality and long-term disability worldwide. Conventional surgical techniques, including craniotomy and catheter-based drainage, are often associated with significant procedural risks and variable outcomes across clinical settings. Minimally invasive approaches have been proposed to reduce surgical trauma, improve precision, and enhance recovery. Recent studies, such as the ENRICH trial, have provided encouraging evidence that selected patients may benefit from early minimally invasive hematoma evacuation, though results remain heterogeneous and further validation is needed across different ICH subtypes and populations.
The RAINBOW-ICH trial has been established to address this critical gap by systematically evaluating the role of AI-assisted, robotic-guided minimally invasive neurosurgery. Advances in robotics and artificial intelligence have enabled neurosurgeons to achieve greater precision in hematoma evacuation, minimize surgical injury, and improve reproducibility of complex procedures. RAINBOW-ICH is designed as a nationwide, multicenter umbrella trial, conducted under a single master protocol, with multiple parallel randomized controlled substudies. Each substudy focuses on a distinct ICH population and directly compares AI-assisted robotic-guided hematoma evacuation with the conventional standard of care relevant to that subgroup. Specifically, RAINBOW-LBH (NCT06484374) evaluates patients with large basal ganglia hemorrhage, RAINBOW-MBH (NCT06465719) addresses moderate basal ganglia hemorrhage, RAINBOW-IVH (NCT06486480) investigates intraventricular hemorrhage, and RAINBOW-BSH (NCT06459427) targets brainstem hemorrhage.
Within each substudy, participants are randomized to receive either AI-assisted robotic-guided minimally invasive neurosurgery or the control intervention, such as conventional craniotomy, external ventricular drainage, or optimized medical management. All substudies are conducted as multicenter RCTs across China, ensuring adequate and rapid recruitment, generalizability, and rigorous evaluation of interventions in diverse clinical environments.
By integrating minimally invasive neurosurgical technologies with a unified multicenter umbrella trial design, RAINBOW-ICH represents the first large-scale effort in China to rigorously test and compare surgical strategies for ICH. The findings are expected to generate high-quality evidence, refine clinical practice, and ultimately improve neurological outcomes for patients with this devastating disease.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| RAINBOW-LBH substudy | Experimental | Procedure: AI-assisted robotic-guided endoscopic hematoma evacuation, Procedure: Conventional craniotomyThis substudy is a prospective, multicenter, randomized, controlled, parallel-group trial with blinded endpoint assessment to evaluate the efficacy and safety of AI-assisted robotic-guided endoscopic hematoma evacuation for patients with large basal ganglia hemorrhage (LBH). |
| RAINBOW-MBH substudy | Experimental | Procedure: AI-assisted robotic-guided puncture and hematoma evacuation, Other: Standard medical managementThis substudy is a prospective, multicenter, randomized, controlled, parallel-group trial with blinded endpoint assessment to evaluate AI-assisted robotic-guided puncture and hematoma evacuation for patients with moderate basal ganglia hemorrhage (MBH). |
| RAINBOW-IVH substudy | Experimental | Procedure: AI-assisted robotic-guided endoscopic ventricular hematoma evacuation plus external ventricular drainage, Procedure: External ventricular drainage (EVD)This substudy is a prospective, multicenter, randomized, controlled, parallel-group trial with blinded endpoint assessment to evaluate AI-assisted robotic-guided endoscopic ventricular hematoma evacuation with external ventricular drainage for patients with intraventricular hemorrhage (IVH) |
| RAINBOW-BSH substudy | Experimental | Procedure: AI-assisted robotic-guided puncture and hematoma evacuation, Other: Standard medical managementThis substudy is a prospective, multicenter, randomized, controlled, parallel-group trial with blinded endpoint assessment to evaluate AI-assisted robotic-guided puncture and hematoma evacuation for patients with brainstem hemorrhage (BSH). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AI-assisted robotic-guided endoscopic hematoma evacuationSurgical removal of hematoma using AI-assisted robotic-guided stereotactic navigation and endoscopic aspiration techniques. | Procedure or surgery | RAINBOW-LBH substudy |
| Conventional craniotomyStandard open surgical evacuation of hematoma through craniotomy. | Procedure or surgery | RAINBOW-LBH substudy |
| AI-assisted robotic-guided puncture and hematoma evacuationAI-assisted robotic-guided stereotactic puncture and aspiration of hematoma. | Procedure or surgery | RAINBOW-BSH substudy, RAINBOW-MBH substudy |
| Standard medical managementGuideline-based conservative therapy without surgical hematoma evacuation. | Other | RAINBOW-BSH substudy, RAINBOW-MBH substudy |
| AI-assisted robotic-guided endoscopic ventricular hematoma evacuation plus external ventricular drainageAI-assisted robotic-guided endoscopic evacuation of ventricular hematoma combined with external ventricular drainage. | Procedure or surgery | RAINBOW-IVH substudy |
| External ventricular drainage (EVD)Conventional ventricular catheter placement for hematoma drainage. | Procedure or surgery | RAINBOW-IVH substudy |
Primary outcome
Utility-weighted modified Rankin Scale (UW-mRS)
Time frame: Umbrella level time frame: 6 months; Substudy specific time frame may differ (details will be included in substudy-specific registration)
The mRS is a 7-level ordinal scale used to evaluate functional outcomes after stroke. The categories are defined as follows: 0 = No symptoms 1. = No significant disability. Able to carry out all usual activities, despite some symptoms. 2. = Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. = Moderate disability. Requires some help, but able to walk unassisted. 4. = Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. = Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. = Dead Utility-weighted modified Rankin Scale (UW-mRS) , which applies utility values to each mRS category as shown below： mRS 0= UW-mRS 1；mRS 1= UW-mRS 0.91; mRS 2= UW-mRS 0.76; mRS 3= UW-mRS 0.65; mRS 4= UW-mRS 0.33; mRS 5= UW-mRS 0; mRS 6= UW-mRS 0.
5 secondary outcomes
Ordinal shift in modified Rankin Scale
Time frame: Umbrella level time frame: 6 months; Substudy specific time frame may differ (details will be included in substudy-specific registration)
Excellent functional neurological outcome
Time frame: Umbrella level time frame: 6 months; Substudy specific time frame may differ (details will be included in substudy-specific registration)
Independent functional neurological outcome
Time frame: Umbrella level time frame: 6 months; Substudy specific time frame may differ (details will be included in substudy-specific registration)
Health Related Quality of Life
Time frame: Umbrella level time frame: 6 months; Substudy specific time frame may differ (details will be included in substudy-specific registration)
Total length of hospital stay
Time frame: Umbrella level time frame: 6 months; Substudy specific time frame may differ (details will be included in substudy-specific registration)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jan 2026.
- A Multicenter, RAndomlzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With Al-assisted Robotic Guidance for Large Basal Ganglia Hemorrhage (RAINBOW-LBH)Link provided by the sponsor.
- A Multicenter, RAndomlzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With Al-assisted Robotic Guidance for Moderate Basal Ganglia Hemorrhage (RAINBOW-MBH)Link provided by the sponsor.
- A Multicenter, RAndomlzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With Al-assisted Robotic Guidance for IntraVentricular Hemorrhage (RAINBOW-IVH)Link provided by the sponsor.
- A Multicenter, RAndomlzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With Al-assisted Robotic Guidance for BrainStem Hemorrhage (RAINBOW-BSH)Link provided by the sponsor.
Related trials for Basal Ganglia Hemorrhage
Not yet recruitingObservational study
Minimally Invasive Surgery for Spontaneous Deep Intracerebral Hemorrhage
Intracerebral Hemorrhage, Spontaneous Intracerebral Hemorrhage
Not yet recruitingObservational study
Immune-Inflammatory Biomarkers in Predicting Early Cognitive Impairment in Adults With Acute Basal Ganglionic Stroke
Stroke, Post-Stroke Cognitive Impairment
Recruiting
Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation
Basal Ganglia Intracerebral Hemorrhage
RecruitingObservational study
Rapid Evacuation and Access of Cerebral Hemorrhage Registry
Intracerebral Hemorrhage
Recruiting
Neurologic Stem Cell Treatment Study
Neurologic Disorders, Nervous System Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing AI-assisted robotic-guided endoscopic hematoma evacuation, Conventional craniotomy and AI-assisted robotic-guided puncture and hematoma evacuation in people with Basal Ganglia Hemorrhage and Intraventricular Hemorrhage, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gao Chen, MD. (+86 0571 87784813, d-chengao@zju.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Utility-weighted modified Rankin Scale (UW-mRS) (time frame: Umbrella level time frame: 6 months; Substudy specific time frame may differ (details will be included in substudy-specific registration)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jan 2026.